Abstract Number: 3147 • 2015 ACR/ARHP Annual Meeting
Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease
Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic…Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…Abstract Number: 3150 • 2015 ACR/ARHP Annual Meeting
Virtual Peer-to-Peer Mentoring Support for Adolescents with Juvenile Idiopathic Arthritis: The Virtual Peer-to-Peer Program
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic disease that results in physical and emotional symptoms as well as difficulties in social and role…Abstract Number: 1468 • 2015 ACR/ARHP Annual Meeting
The Proposed Outcome Parameters of the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) with Uveitis Disability VAS Score Correspond Significantly with Uveitis “Classicaly Assessed” Uveitis Activity
Background/Purpose: Juvenile idiopathic arthritis (JIA) associated uveitis is one of the most severe comorbidities of JIA and occurs in around 10% of JIA patients. There…Abstract Number: 3178 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases
Background/Purpose: To assess the efficacy of Tocilizumab (TCZ) in refractory uveitis associated to juvenile idiopathic arthritis (JiA).Methods: Multicenter study of uveitis related to JiA…Abstract Number: 1470 • 2015 ACR/ARHP Annual Meeting
A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects
Background/Purpose: The impact of juvenile idiopathic arthritis (JIA) is not confined to joint involvement in children but rather widespread effects extending to adulthood. This study…Abstract Number: 3245 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Physical Activity in Older Children with Juvenile Idiopathic Arthritis
Background/Purpose: The purpose of this study was to examine factors associated with physical activity (PA) in children with JIA. PA is important for the physical,…Abstract Number: 1475 • 2015 ACR/ARHP Annual Meeting
Fatigue, Quality of SLEEP and PAIN in Children with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children (1). Children with…Abstract Number: 1479 • 2015 ACR/ARHP Annual Meeting
Qualitative Assessment of Patient Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Background/Purpose: The aim of this study was to identify and characterize the factors that JIA patients in young adulthood use to define a successful disease…Abstract Number: 1482 • 2015 ACR/ARHP Annual Meeting
Temporomandibular Pain in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Joint pain is a primary symptom in Juvenile Idiopathic Arthritis (JIA). Experience of pain has been shown to be a significant predictor of impaired…Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting
A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…Abstract Number: 2171 • 2015 ACR/ARHP Annual Meeting
A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis
Background/Purpose: Although there is a higher frequency of adverse maternal outcomes in mother with rheumatoid arthritis, little is known regarding mothers with juvenile idiopathic arthritis…Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…Abstract Number: 1444 • 2014 ACR/ARHP Annual Meeting
The Vocational Experiences of Young People with Juvenile Idiopathic Arthritis and the Role of the Multidisciplinary Team Supporting Positive Employment Outcomes
Background/Purpose: Recent decades have seen marked changes in the management of juvenile idiopathic arthritis (JIA), with improved clinical outcomes for many patients. However, unemployment rates…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 19
- Next Page »